# Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer

> **NCT00365599** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 43 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** suberoylanilide hydroxamic acid (SAHA, Vorinostat)
- **DRUG:** tamoxifen citrate (Tamoxifen)

## Key facts

- **NCT ID:** NCT00365599
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2011-04
- **Final completion:** 2012-08
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2014-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00365599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00365599, "Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00365599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*